文献速递头颈外科咽喉与嗓音

诱导化疗治疗喉癌中的贫血与中性粒细胞与淋巴细胞比值

Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy.
PubMed 文献 · Laryngoscope · 2019-04-22

这项回顾性单中心病例系列分析了68例接受保留方案诱导化疗的T3喉癌患者,评估治疗前及诱导化疗后中性粒细胞与淋巴细胞比值(NLR)和血红蛋白水平与化疗反应及生存的关系。治疗前NLR>5和贫血均与较短的总生存期和无病生存期相关,且独立于化疗反应。

要点

  • 治疗前NLR>5和贫血均与较短的总生存期和无病生存期相关。
  • 治疗前NLR和贫血与化疗反应无关联。
  • 治疗前NLR和贫血是唯一与生存结局显著相关的因素。

核心结论

  • 在接受保留方案治疗的喉癌患者中,诱导化疗前高NLR和贫血与较短生存相关,且独立于化疗反应。

研究设计与样本

  • 回顾性单中心病例系列,分析68例接受保留方案诱导化疗的T3喉癌患者。

主要发现

  • 诱导化疗前后中位NLR分别为2.76和2.01,中位血红蛋白分别为14.5 g/dL和11.6 g/dL。
  • 治疗前NLR与贫血不相关,且均与化疗反应无关联。
  • 治疗前NLR>5和贫血均与较短的总生存期和无病生存期相关。
  • 治疗前NLR>5和贫血是唯一与生存结局显著相关的因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: We studied the influence of the neutrophil-to-lymphocyte ratio (NLR) and anemia on the response to induction chemotherapy (IC) and survival outcomes in laryngeal cancer patients treated with a preservation protocol. STUDY DESIGN: Retrospective single-center case series. METHODS: We analyzed patients with T3 laryngeal cancer treated with IC using a preservation protocol. The NLR and hemoglobin levels were assessed before treatment and after IC. The response to chemotherapy was assessed using Response Evaluation Criteria in Solid Tumours 1.1 and World Heath Organization standards. The oncological endpoints were overall survival (OS) and disease-free survival (DFS). RESULTS: Sixty-eight patients were analyzed. The median NLR and hemoglobin levels before and after IC were 2.76 and 14.5 g/dL, and 2.01 and 11.6 g/dL, respectively. The NLR and anemia before treatment were not correlated, and they were not associated with the response to chemotherapy. However, an NLR > 5 and anemia before treatment were both associated with shorter OS and DFS. Notably, they were the only factors found to be significantly associated with survival outcomes. CONCLUSIONS: In laryngeal cancer, patients treated with a preservation protocol, a high NLR ratio, and anemia before IC were associated with shorter survival, independently of the response to chemotherapy. LEVEL OF EVIDENCE: 4 Laryngoscope, 130:E144-E150, 2020.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Gorphe P, Bouhir S, Garcia GCTE, et al. Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy. Laryngoscope. 2019. PMID: 31006874. doi:10.1002/lary.28021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。